Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
Open Access
- 1 February 1987
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 79 (2), 478-482
- https://doi.org/10.1172/jci112837
Abstract
Trimetrexate, a highly lipid-soluble quinazoline antifolate now undergoing trials as an anticancer agent, was found to be a potent inhibitor of the dihydrofolate reductase (DHFR) isolated from Toxoplasma gondii. The concentration required for 50% inhibition of protozoal DHFR was 1.4 nM. As an inhibitor of this enzyme, trimetrexate was almost 600-fold (amount of antifolate required to inhibit catalytic reaction by 50%) and 750-fold (inhibition constant) more potent than pyrimethamine, the DHFR inhibitor currently used to treat toxoplasma infection. When the protozoan was incubated with 1 microM trimetrexate, the drug rapidly reached high intracellular concentrations. Since toxoplasma organisms lack a transmembrane transport system for physiologic folates, host toxicity can be prevented by co-administration of the reduced folate, leucovorin, without reversing the antiprotozoal effect. The effectiveness of trimetrexate against toxoplasma was demonstrated both in vitro and vivo. Proliferation of toxoplasma in murine macrophages in vitro was completely inhibited by exposure of these cells to 10(-7) M trimetrexate for 18 h. When used alone, trimetrexate was able to extend the survival of T. gondii-infected mice.Keywords
This publication has 14 references indexed in Scilit:
- A re-evaluation of the competitive protein binding assay for methotrexate binding to dihydrofolate reductaseBiochemical Pharmacology, 1986
- Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analoguesBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1986
- Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 1984
- Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitroBiochemical Pharmacology, 1984
- Pneumocystis carinii Pneumonia: A Comparison Between Patients with the Acquired Immunodeficiency Syndrome and Patients with Other ImmunodeficienciesAnnals of Internal Medicine, 1984
- Transport routes utilized by L1210 cells for the influx and efflux of methotrexate.Journal of Biological Chemistry, 1984
- A simple procedure for the synthesis of high specific activity tritiated (6S)-5-formyltetrahydrofolateAnalytical Biochemistry, 1982
- Competitive protein binding assay for methotrexate.Proceedings of the National Academy of Sciences, 1975
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- THE INTERACTION BETWEEN TOXOPLASMA GONDII AND MAMMALIAN CELLSThe Journal of Experimental Medicine, 1972